PL1603915T3 - Podstawione pochodne 8-pirydynylo-dihydrospiro-cykloalkilo-pirymido-1,2-a-pirymidyn-6-onu i 8-pirymidynylo-dihydrospiro-cykloalkilo-pirymido-1,2-a-pirymidyn-6-onu oraz ich zastosowanie przeciwko chorobom neurodegeneracyjnym - Google Patents

Podstawione pochodne 8-pirydynylo-dihydrospiro-cykloalkilo-pirymido-1,2-a-pirymidyn-6-onu i 8-pirymidynylo-dihydrospiro-cykloalkilo-pirymido-1,2-a-pirymidyn-6-onu oraz ich zastosowanie przeciwko chorobom neurodegeneracyjnym

Info

Publication number: PL1603915T3
Authority: PL; Poland
Prior art keywords: pyrimidin; dihydrospiro; pyrimido; cycloalkyl; pyridinyl
Prior art date: 2003-03-07

Application number

PL04717643T

Other languages

English (en)

Inventor

Pascal George

Alistair Lochead

Mourad Saady

Franck Slowinski

Philippe Yaiche

Original Assignee

Sanofi Aventis

Mitsubishi Tanabe Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-07

Filing date

2004-03-05

Publication date

2010-10-29

2004-03-05 Application filed by Sanofi Aventis, Mitsubishi Tanabe Pharma Corp filed Critical Sanofi Aventis

2010-10-29 Publication of PL1603915T3 publication Critical patent/PL1603915T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PL04717643T 2003-03-07 2004-03-05 Podstawione pochodne 8-pirydynylo-dihydrospiro-cykloalkilo-pirymido-1,2-a-pirymidyn-6-onu i 8-pirymidynylo-dihydrospiro-cykloalkilo-pirymido-1,2-a-pirymidyn-6-onu oraz ich zastosowanie przeciwko chorobom neurodegeneracyjnym PL1603915T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP03290569A EP1454909B1 (en)	2003-03-07	2003-03-07	8'-pyridinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) pyrimido (1,2-a) pyrimidin-6 derivatives -one and their use against neurodegenerative diseases
EP04717643A EP1603915B1 (en)	2003-03-07	2004-03-05	SUBSTITUTED 8 -PYRIDINYL-DIHYDROSPIRO- CYCLOALKYL -PYRIMIDO 1,2-a PYRIMIDIN-6-ONE AND 8 -PYRIMIDIN YL-DIHYDROSPIRO- CYCLOALKYL -PYRIMIDO 1,2-a PYRIMIDIN-6-ONE DERIVATIVES AND THEIR USE AGAINST NEUROGENERATIVE DISEASES
PCT/EP2004/003051 WO2004078760A1 (en)	2003-03-07	2004-03-05	SUBSTITUTED 8'-PYRIDINYL-DIHYDROSPIRO-[CYCLOALKYL]-PYRIMIDO [1,2-a] PYRIMIDIN-6-ONE AND 8'-PYRIMIDINYL-DIHYDROSPIRO-[CYCLOALKYL]-PYRIMIDO [1,2-a] PYRIMIDIN-6-ONE DERIVATIVES AND THEIR USE AGAINST NEUROGENERATIVE DISEASES

Publications (1)

Publication Number	Publication Date
PL1603915T3 true PL1603915T3 (pl)	2010-10-29

Family

ID=32799103

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04717643T PL1603915T3 (pl)	2003-03-07	2004-03-05	Podstawione pochodne 8-pirydynylo-dihydrospiro-cykloalkilo-pirymido-1,2-a-pirymidyn-6-onu i 8-pirymidynylo-dihydrospiro-cykloalkilo-pirymido-1,2-a-pirymidyn-6-onu oraz ich zastosowanie przeciwko chorobom neurodegeneracyjnym

Country Status (25)

Country	Link
US (2)	US7294632B2 (pl)
EP (2)	EP1454909B1 (pl)
JP (1)	JP4639182B2 (pl)
KR (1)	KR101069984B1 (pl)
CN (1)	CN100463908C (pl)
AR (1)	AR043485A1 (pl)
AT (1)	ATE469153T1 (pl)
AU (1)	AU2004218250B2 (pl)
BR (1)	BRPI0408189A (pl)
CA (1)	CA2516937C (pl)
CY (1)	CY1111057T1 (pl)
DE (1)	DE602004027354D1 (pl)
DK (1)	DK1603915T3 (pl)
EA (1)	EA008172B1 (pl)
ES (1)	ES2346311T3 (pl)
IL (1)	IL170461A (pl)
MX (1)	MXPA05009574A (pl)
NO (1)	NO20054140L (pl)
NZ (1)	NZ542135A (pl)
PL (1)	PL1603915T3 (pl)
PT (1)	PT1603915E (pl)
SI (1)	SI1603915T1 (pl)
TW (1)	TWI320785B (pl)
WO (1)	WO2004078760A1 (pl)
ZA (1)	ZA200507107B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20080025079A (ko) *	2005-06-14	2008-03-19	쉐링 코포레이션	아스파르틸 프로테아제 억제제
EP2258357A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en)	2005-08-26	2007-03-01	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
JP2009512711A (ja)	2005-10-21	2009-03-26	ブレインセルス，インコーポレイティド	Ｐｄｅ阻害による神経新生の調節
US20070112017A1 (en)	2005-10-31	2007-05-17	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2382975A3 (en)	2006-05-09	2012-02-29	Braincells, Inc.	Neurogenesis by modulating angiotensin
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
EP1992625A1 (en) *	2007-05-16	2008-11-19	Sanofi-Aventis	Arylamide pyrimidone compounds
EP1992620A1 (en) *	2007-05-16	2008-11-19	Sanofi-Aventis	Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
EP1992624A1 (en)	2007-05-16	2008-11-19	Sanofi-Aventis	Heteroarylamide pyrimidone compounds
EP1992621A1 (en)	2007-05-16	2008-11-19	Sanofi-Aventis	Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
EP2138485A1 (en)	2008-06-26	2009-12-30	sanofi-aventis	Substituted N-Oxide pyrazine derivatives
EP2138498A1 (en) *	2008-06-26	2009-12-30	sanofi-aventis	Substituted tricyclic derivatives against neurodegenerative diseases
EP2138495A1 (en)	2008-06-26	2009-12-30	sanofi-aventis	Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives
EP2138493A1 (en)	2008-06-26	2009-12-30	Sanofi-Aventis	Substituted pyrimidone derivatives
EP2138488A1 (en)	2008-06-26	2009-12-30	sanofi-aventis	4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
EP2138494A1 (en)	2008-06-26	2009-12-30	Sanofi-Aventis	Substituted alkyl pyrimidin-4-one derivatives
EP2138492A1 (en)	2008-06-26	2009-12-30	Sanofi-Aventis	Substituted pyrimidin-4-one derivatives
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
BRPI1015943A8 (pt)	2009-07-02	2018-01-09	Sanofi Sa	derivados de 1,2,3,4-tetra - hidro - pirimido {1,2-a} pirimidin-6-ona, o respectivo preparo e a respectiva utilização farmacêutica.
HUE024504T2 (en)	2010-12-23	2016-01-28	Sanofi Sa	Pyrimidine derivatives, a process for their preparation and their use in medicine
FR2992314B1 (fr)	2012-06-22	2015-10-16	Sanofi Sa	Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
FR2992316A1 (fr)	2012-06-22	2013-12-27	Sanofi Sa	Derives de pyrimidinones, leur preparation et leur application en therapeutique
WO2015155738A2 (en)	2014-04-09	2015-10-15	Christopher Rudd	Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2812636A1 (fr) *	2000-08-02	2002-02-08	Novapharme	Nouveaux derives 2-phenyl imidazo[1.2-a]pyrimidin-5-ones et 2-phenyl 2,3-dihydro imidazo[1,2-a]pyrimidin-5-ones
EP1184383A1 (en) *	2000-09-01	2002-03-06	Sanofi-Synthelabo	9-[Alkyl], 9-[(heteroaryl)alkyl] and 9-[(aryl)alkyl]-2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives
CN1267432C (zh) *	2000-09-01	2006-08-02	赛诺菲-安万特	2－吡啶基－6,7,8,9－四氢嘧啶并[1,2－a]嘧啶－4－酮和7－吡啶基－2,3－二氢咪唑并[1,2－a]嘧啶－5(1H)酮衍生物
EP1184385A1 (en) *	2000-09-01	2002-03-06	Sanofi-Synthelabo	1-[Alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one derivatives
EP1295884A1 (en) *	2001-09-21	2003-03-26	Sanofi-Synthelabo	2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives
CN1247585C (zh) *	2001-09-21	2006-03-29	赛诺菲安万特	取代的2－吡啶基－6,7,8,9－四氢嘧啶并[1,2－a]嘧啶－4－酮及7－吡啶基－2,3－二氢咪唑并[1,2－a]嘧啶－5(1h)酮衍生物
EP1295885A1 (en) *	2001-09-21	2003-03-26	Sanofi-Synthelabo	Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives
CN1247586C (zh) *	2001-09-21	2006-03-29	赛诺菲安万特	治疗神经退化性疾病的取代的2－嘧啶基－6,7,8,9－四氢嘧啶并[1,2－a]嘧啶－4－酮及7－嘧啶基－2,3－二氢咪唑并[1,2－a]嘧啶－5(1h)酮衍生物

2003
- 2003-03-07 EP EP03290569A patent/EP1454909B1/en not_active Expired - Lifetime
2004
- 2004-03-05 AT AT04717643T patent/ATE469153T1/de active
- 2004-03-05 WO PCT/EP2004/003051 patent/WO2004078760A1/en not_active Ceased
- 2004-03-05 ES ES04717643T patent/ES2346311T3/es not_active Expired - Lifetime
- 2004-03-05 MX MXPA05009574A patent/MXPA05009574A/es active IP Right Grant
- 2004-03-05 EP EP04717643A patent/EP1603915B1/en not_active Expired - Lifetime
- 2004-03-05 PL PL04717643T patent/PL1603915T3/pl unknown
- 2004-03-05 TW TW093105914A patent/TWI320785B/zh not_active IP Right Cessation
- 2004-03-05 AU AU2004218250A patent/AU2004218250B2/en not_active Ceased
- 2004-03-05 CA CA2516937A patent/CA2516937C/en not_active Expired - Fee Related
- 2004-03-05 AR ARP040100694A patent/AR043485A1/es not_active Application Discontinuation
- 2004-03-05 JP JP2006504813A patent/JP4639182B2/ja not_active Expired - Fee Related
- 2004-03-05 CN CNB2004800109973A patent/CN100463908C/zh not_active Expired - Fee Related
- 2004-03-05 EA EA200501241A patent/EA008172B1/ru not_active IP Right Cessation
- 2004-03-05 DE DE602004027354T patent/DE602004027354D1/de not_active Expired - Lifetime
- 2004-03-05 BR BRPI0408189-7A patent/BRPI0408189A/pt not_active IP Right Cessation
- 2004-03-05 PT PT04717643T patent/PT1603915E/pt unknown
- 2004-03-05 NZ NZ542135A patent/NZ542135A/en not_active IP Right Cessation
- 2004-03-05 SI SI200431465T patent/SI1603915T1/sl unknown
- 2004-03-05 DK DK04717643.3T patent/DK1603915T3/da active
- 2004-03-05 ZA ZA200507107A patent/ZA200507107B/en unknown
2005
- 2005-08-23 IL IL170461A patent/IL170461A/en not_active IP Right Cessation
- 2005-09-06 NO NO20054140A patent/NO20054140L/no not_active Application Discontinuation
- 2005-09-06 KR KR1020057016622A patent/KR101069984B1/ko not_active Expired - Fee Related
- 2005-09-07 US US11/220,999 patent/US7294632B2/en not_active Expired - Fee Related
2007
- 2007-10-02 US US11/866,142 patent/US7507743B2/en not_active Expired - Fee Related
2010
- 2010-08-17 CY CY20101100761T patent/CY1111057T1/el unknown

Also Published As

Publication number	Publication date
NZ542135A (en)	2008-06-30
CN1777607A (zh)	2006-05-24
TWI320785B (en)	2010-02-21
PT1603915E (pt)	2010-07-22
AU2004218250B2 (en)	2010-02-25
BRPI0408189A (pt)	2006-03-21
EA200501241A1 (ru)	2006-04-28
HK1085740A1 (en)	2006-09-01
NO20054140L (no)	2005-12-02
MXPA05009574A (es)	2006-05-19
EP1454909B1 (en)	2008-08-20
JP2006519814A (ja)	2006-08-31
EP1603915B1 (en)	2010-05-26
CA2516937C (en)	2011-10-25
ZA200507107B (en)	2006-11-29
US7507743B2 (en)	2009-03-24
US7294632B2 (en)	2007-11-13
DE602004027354D1 (de)	2010-07-08
AU2004218250A1 (en)	2004-09-16
CA2516937A1 (en)	2004-09-16
TW200510418A (en)	2005-03-16
NO20054140D0 (no)	2005-09-06
US20080081819A1 (en)	2008-04-03
EA008172B1 (ru)	2007-04-27
EP1603915A1 (en)	2005-12-14
ES2346311T3 (es)	2010-10-14
CN100463908C (zh)	2009-02-25
KR20050106500A (ko)	2005-11-09
SI1603915T1 (sl)	2010-08-31
DK1603915T3 (da)	2010-08-30
JP4639182B2 (ja)	2011-02-23
US20060025431A1 (en)	2006-02-02
EP1454909A1 (en)	2004-09-08
IL170461A (en)	2011-11-30
WO2004078760A1 (en)	2004-09-16
AR043485A1 (es)	2005-08-03
CY1111057T1 (el)	2015-06-11
ATE469153T1 (de)	2010-06-15
KR101069984B1 (ko)	2011-10-04

Publication	Publication Date	Title
SI1603915T1 (sl)	2010-08-31	SUBSTITUIRANI 8-PIRIDINIL-DIHIDROSPIRO-CIKLOALKIL-PIRIMIDO 1,2-a PIRIMIDIN-6-ONSKI IN 8-PIRIMIDINIL-DIHIDROSPIRO-CIKLOALKIL-PIRIMIDO 1,2-a PIRIMIDIN-6-ONSKI DERIVATI IN NJIHOVA UPORABA PROTI NEVRODEGENERATIVNIM BOLEZNIM
EP1599482A4 (en)	2008-10-01	PYRAZOLO1,5-A PYRIMIDINE DERIVATIVES
ZA200605901B (en)	2007-12-27	Pyrazolo [3,4-B] pyridine compounds, and their use as phosphodiesterase inhibitors
PL377239A1 (pl)	2006-01-23	Nowe amino-podstawione pochodne dihydropirymido [4,5-d]-pirymidynonu, ich wytwarzanie i zastosowanie jako środków framaceutycznych
PL377660A1 (pl)	2006-02-06	Podstawione przy azocie pochodne heksahydropirazyno [1,2-a] pirymidyno-4,7-dionu, sposób ich wytwarzania i ich zastosowanie jako środków leczniczych
IL176737A0 (en)	2006-10-31	Pyrazolo[1,5-a] pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
IL219669A0 (en)	2012-06-28	PYRAZOLO [1,5-a]PYRIDINES AND USE THEREOF IN THE PREPARATION OF A MEDICAMENT
IL166100A0 (en)	2006-01-15	7,8,9-10-tetrahydro-6h-azepino,6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrroloÄ2,1-bÜ quinazolinone derivatives
DE60206946D1 (de)	2005-12-01	Substituierte 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)onderivate gegen neurodegenerative erkrankungen
IL173395A0 (en)	2006-06-11	Pyridazine derivatives and their use as therapeutic agents
IL183110A0 (en)	2007-09-20	Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
ZA200406362B (en)	2006-02-22	N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials.
PL1699795T3 (pl)	2008-01-31	Podstawione pochodne 8’-piry(mi)dynylo-dihydrospiro-[cykloalkiloamino]-pirymido[1,2-a]pirymidyn-6-onu
AU2003249909A1 (en)	2004-01-19	Phenoxypropenylphenyl derivatives and their use as herbicides
IL170680A0 (en)	2009-02-11	8 - SUBSTITUTED - 6,7,8,9 -TETRAHYDROPYRIMIDO [1,2-a] PYRIMIDIN - 4 - ONE DERIVATIVES
IL174512A0 (en)	2006-08-01	Pyrazolo and imidazo-pyrimidine derivatives
IL160402A0 (en)	2004-07-25	Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido {1,2-a} pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo{1,2-pyrimidin-5 (1h) one derivatives
ZA200507192B (en)	2007-03-28	Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido [1,2-A] pyrimidin-4-one derivatives
NO20043565L (no)	2004-11-25	Heteroaryl-substituerte 2-pyridinyl- og 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater.
AU2003255323A8 (en)	2004-02-23	Imidazo`1,2-a pyridines
HRP20041157A2 (en)	2005-06-30	Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
SI1487828T1 (sl)	2009-04-30	Morfolinil-sečninski derivati za uporabo pri zdravljenu vnetnih bolezni
AU2003292381A1 (en)	2004-07-14	Naphthyridine derivatives and their use as fungicides
TWI320413B (en)	2010-02-11	1,4-diazabicyclo [ 3.2.2 ] nonanecarboxamide derivatives, preparation thereof and therapeutic use thereof
IL173445A0 (en)	2006-06-11	6-(1,1-difluoroalkyl)-4-aminopicolinates and their use as herbicides